A Second Dose of Measles Vaccine (MV) in the Second Year of Life

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

3812 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2021-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life. Half of the study participants will receive a second dose of measles vaccine at 18 months of age while the other half will receive a second dose of measles by 4 years of age or at the end of the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Additional Measles Vaccine at 4 Months of Age

NCT01486355

Measles Infection

UNKNOWN PHASE4

Measles Vaccination at Health System Contacts

NCT04220671

Measles Vaccine Hospital Admission Mortality +1 more

ENROLLING_BY_INVITATION PHASE4

Trial of Additional Measles Vaccine to Reduce Child Mortality

NCT01644721

Measles Vaccine

COMPLETED PHASE4

Non-Specific Effects of Standard Titre Measles Vaccination

NCT00168662

Measles

COMPLETED PHASE4

Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.

NCT01668745

Measles Vaccine

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Child Mortality Child Morbidity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Measles vaccine

Measles vaccine, 1 dose of 0.5 ml

Group Type EXPERIMENTAL

Measles vaccine

Intervention Type BIOLOGICAL

Control

Nothing

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Measles vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children need to have received the third dose of inactivated vaccines (Penta, PCV13 and IPV) before measles vaccination.

Exclusion Criteria

* Having severe malformations that impairs their health
* Having received a second dose of measles vaccine
* Severely ill (requiring hospitalization) upon clinical examination

Minimum Eligible Age

18 Months

Maximum Eligible Age

24 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes